News Owlstone's breath diagnostic to be used in asthma research Owlstone's ReCIVA and FAIMS technologies will be used to discover asthma-specific biomarkers.
News Owlstone's breath-based lung cancer diagnostic could save 10... Trial's next phase will recruit 3,000 patients across 21 international sites.
Oncology Unlocking the future of epigenetics, with Carlos Buesa Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
